BullishAgent BullishAgent SEC Filings Earnings Calendar Analyst Ratings IPOs Insiders Institutional Funds Screener
Sign in Register

LSF

Laird Superfood, Inc. AMEX
Consumer Defensive ·Packaged Foods ·US · lairdsuperfood.com
$3.10
Mkt Cap $33.9M
52w Low $1.96 19.1% of range 52w High $7.94
50d MA $2.63 200d MA $3.90
P/E (TTM) -10.1x
EV/EBITDA -5.8x
P/B 2.9x
Debt/Equity 0.0x
ROE -28.4%
P/FCF -8.2x
RSI (14)
ATR (14)
Beta 2.51
50d MA $2.63
200d MA $3.90
Avg Volume 58.7K
About
Laird Superfood, Inc. manufactures and markets plant-based natural and functional food in the United States. It offers powdered and liquid coffee creamers, and hydration and beverage enhancing supplements; hydrate coconut water products, activate daily jumpstart products, activate prebiotic daily greens, renew plant-based proteins, and performance mushroom supplements; coffee, tea, hot chocolate p…
Recent Earnings
Date Time Est Rptd Surp Base Gap% D1% D2% D3% D4% D5% 1M% Guide ▲★
Mar 26, 2026 AMC -0.06 -0.17 -183.3% 2.25 -11.1% -8.9% -5.3% -4.4% +5.3% +9.8% +48.0%
Nov 10, 2025 AMC -0.04 -0.03 +25.0% 4.18 -28.0% -31.1% -35.2% -33.7% -36.1% -40.0% -42.8%
Aug 6, 2025 AMC -0.07 -0.03 +57.1% 7.14 -4.3% -15.4% -16.7% -20.2% -19.5% -11.5% -19.5%
May 7, 2025 AMC -0.07 -0.02 +71.4% 6.72 +4.0% +4.9% +11.6% +12.5% +11.6% +10.4% -0.1%
Feb 26, 2025 AMC -0.02 -0.04 -100.0% 7.19 -17.1% -16.6% -13.1% -16.8% -18.6% -27.1% -12.7%
Nov 6, 2024 AMC -0.06 -0.05 +16.7% 7.37 +8.5% +21.7% +24.3% +35.5% +21.6% +14.0% +22.1%
Aug 7, 2024 AMC -0.10 -0.03 +70.0% 4.50 +4.4% +0.0% -1.1% -2.7% +0.2% -3.1% -20.4%
May 8, 2024 AMC -0.20 -0.11 +45.0% 2.64 +10.2% +4.9% +1.9% +1.5% +1.5% -1.5% +64.8%
Mar 12, 2024 AMC -0.23 0.02 +108.7% 0.93 +40.9% +104.3% +157.0% +245.2% +176.3% +150.5% +179.6%
Nov 8, 2023 AMC -0.35 -0.28 +20.0% 0.85 +4.7% +5.8% +2.5% -13.0% -5.5% -2.4% +23.5%
Recent Analyst Ratings
Date Firm Action Grade Target Base Open Gap% D1% D2% D3% D4% D5%
Mar 30 Maxim Group Maintains Buy → Buy $2.05 $2.07 +1.0% +3.9% +4.9% +15.6% +20.5% +22.0%
Nov 7 Roth MKM Maintains Buy → Buy $7.37 $8.00 +8.5% +21.7% +24.3% +35.5% +21.6% +14.0%
Aug 8 Roth MKM Maintains Buy → Buy $4.50 $4.70 +4.4% +0.0% -1.1% -2.7% +0.2% -3.1%
May 9 Canaccord Genuity Maintains Buy → Buy $2.64 $2.91 +10.2% +4.9% +1.9% +1.5% +1.5% -1.5%
May 9 Roth MKM Upgrade Neutral → Buy $2.64 $2.91 +10.2% +4.9% +1.9% +1.5% +1.5% -1.5%
Mar 13 Roth MKM Maintains Neutral → Neutral $0.93 $1.31 +40.9% +104.3% +157.0% +245.2% +176.3% +150.5%
Mar 9 Canaccord Genuity Maintains Buy → Buy $3.99 $4.01 +0.5% -4.0% -8.0% -16.5% -23.3% -24.6%
Jan 4 Roth Capital Downgrade Buy → Neutral $13.56 $13.73 +1.3% +2.9% +0.0% +3.7% -4.1% -11.9%
Aug 12 Roth Capital Downgrade Buy → Neutral $24.66 $22.19 -10.0% -19.2% -12.8% -11.9% -12.8% -20.4%
Aug 11 Roth Capital Downgrade Buy → Neutral $24.46 $24.48 +0.1% +0.8% -18.5% -12.1% -11.2% -12.1%
Recent Filings
8-K · 7.01 ! Medium
Laird Superfood, Inc. -- 8-K 7.01: Regulation FD Disclosure
Laird Superfood disclosed a presentation regarding its Terrasoul Acquisition, providing summary information for investors to contextualize the deal alongside SEC filings and future announcements.
Apr 22
8-K · 2.01 !!! Very High
Laird Superfood, Inc. -- 8-K 2.01: Acquisition Completed
Laird Superfood completed its acquisition of Nexus Capital Management, expanding its business portfolio and potentially enhancing investment capabilities for shareholders.
Apr 21
8-K · 2.01 !!! Very High
Unknown — 8-K 2.01: Acquisition Completed
LSF completed an acquisition that expands its asset base and diversifies its investment portfolio, potentially increasing future management fees and earnings power for shareholders.
Apr 6
8-K
Unknown — 8-K Filing
Laird Superfood achieved 15% revenue growth to $49.9M in fiscal 2025, demonstrating solid operational momentum that could justify valuation if profitability improves alongside sales expansion.
Mar 26
8-K · 5.02 !!! Very High
Unknown — 8-K 5.02: Executive Change
Executive severance provisions create contingent liabilities and signal potential leadership transition risk, which investors should monitor as management changes can significantly impact company strategy and stock performance.
Mar 19
8-K · 2.01 !!! Very High
Unknown — 8-K 2.01: Acquisition Completed
Ligand Pharmaceuticals completed an asset acquisition that could expand its portfolio and revenue streams, making the stock potentially more attractive if the acquired assets have strong commercial prospects.
Mar 12
Data updated apr 25, 2026 7:56pm · Source: massive.com